Graft-versus-host disease epidemiology and demographics
|
Graft-versus-host disease |
|
Differentiating Graft-versus-host disease from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Graft-versus-host disease epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Graft-versus-host disease epidemiology and demographics |
|
FDA on Graft-versus-host disease epidemiology and demographics |
|
CDC on Graft-versus-host disease epidemiology and demographics |
|
Graft-versus-host disease epidemiology and demographics in the news |
|
Blogs on Graft-versus-host disease epidemiology and demographics |
|
Risk calculators and risk factors for Graft-versus-host disease epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Shyam Patel [2]
Overview
There are no racial or geographic disparities regarding the prevalence of GvHD. GvHD carries a high morbidity rate across all subgroups of patients.
Epidemiology and Demographics
GvHD affects 30-70% of patients who undergo allogeneic transplant.[1] It accounts for 15-30% of deaths after stem cell transplant.[2] It is not an uncommon complication of stem cell transplant. It tends to occur more often in patients who have less genetic similarity compared to their donors. It typically occurs within the first 100 days of transplant (acute GvHD) (approximately 90-95% of cases), though it can also occur after the 100-day time point (chronic GvHD).[1] It is thought to occur more commonly in men and in patients who receive donor stem cells from female multiparous donors, as there is a higher probability for HLA disparity in this group. There are no specific racial disparities in GvHD. It can occur in persons of any race.
The Center for International Blood and Marrow Transplant Research performed an analysis of data collected between 1999 and 2005 showing that the overall incidence of grades 2-4 GvHD was 39% in patients who received stem cells from sibling donors and 59% in patients who received stem cells from unrelated donors.[3] It is important to note that the incidence of GvHD varies depending on the aggressiveness of diagnostic workup. If clinicians pursue diagnostic strategies like such as skin biopsy, liver biopsy, endoscopy, or colonoscopy even with minimal symptoms, a pathologic diagnosis may be present and a patient may be diagnosed with GvHD.[3]
References
- ↑ 1.0 1.1 Lee SJ (2010). "Have we made progress in the management of chronic graft-vs-host disease?". Best Pract Res Clin Haematol. 23 (4): 529–35. doi:10.1016/j.beha.2010.09.016. PMC 3053022. PMID 21130418.
- ↑ Schroeder MA, DiPersio JF (2011). "Mouse models of graft-versus-host disease: advances and limitations". Dis Model Mech. 4 (3): 318–33. doi:10.1242/dmm.006668. PMC 3097454. PMID 21558065.
- ↑ 3.0 3.1 Rezvani AR, Storb RF (2012). "Prevention of graft-vs.-host disease". Expert Opin Pharmacother. 13 (12): 1737–50. doi:10.1517/14656566.2012.703652. PMC 3509175. PMID 22770714.